{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:21:29Z","timestamp":1778102489468,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"CareDx"},{"name":"Shire ViroPharma"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1053\/j.ackd.2019.12.002","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T03:08:19Z","timestamp":1592190499000},"page":"138-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Complement-Based Therapy in the Management of Antibody-Mediated Rejection"],"prefix":"10.1053","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-7428","authenticated-orcid":false,"given":"Anshul","family":"Bhalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Alachkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7154-0889","authenticated-orcid":false,"given":"Sami","family":"Alasfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ackd.2019.12.002_bib1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellares","year":"2012","journal-title":"Am J Transpl"},{"issue":"11","key":"10.1053\/j.ackd.2019.12.002_bib2","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.12.002_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transpl"},{"issue":"8","key":"10.1053\/j.ackd.2019.12.002_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.12.002_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.12.002_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation","volume":"280","author":"Patel","year":"1969","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1053\/j.ackd.2019.12.002_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajt.14584","article-title":"Antibody-mediated rejection: new approaches in prevention and management","volume":"18","author":"Montgomery","year":"2018","journal-title":"Am J Transpl"},{"key":"10.1053\/j.ackd.2019.12.002_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.molimm.2019.06.002","article-title":"The role of complement in antibody mediated transplant rejection","volume":"112","author":"Thurman","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1053\/j.ackd.2019.12.002_bib9","doi-asserted-by":"crossref","first-page":"678180","DOI":"10.1155\/2013\/678180","article-title":"The importance of C4d in biopsies of kidney transplant recipients","volume":"2013","author":"Correa","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1053\/j.ackd.2019.12.002_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ajt.13434","article-title":"Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation","volume":"16","author":"Orandi","year":"2016","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2019.12.002_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-6143.2010.03364.x","article-title":"Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)","volume":"11","author":"Loupy","year":"2011","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.12.002_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/tri.12706","article-title":"Complement inhibition as potential new therapy for antibody-mediated rejection","volume":"29","author":"Eskandary","year":"2016","journal-title":"Transpl Int"},{"issue":"11","key":"10.1053\/j.ackd.2019.12.002_bib13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.12.002_bib14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2019.12.002_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.transproceed.2017.12.015","article-title":"Eculizumab for prevention of antibody-mediated rejection in blood group-incompatible renal transplantation","volume":"50","author":"West-Thielke","year":"2018","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1053\/j.ackd.2019.12.002_bib16","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transpl"},{"issue":"10","key":"10.1053\/j.ackd.2019.12.002_bib17","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am J Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2019.12.002_bib18","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.15175","article-title":"Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies","volume":"19","author":"Schinstock","year":"2019","journal-title":"Am J Transpl"},{"issue":"2","key":"10.1053\/j.ackd.2019.12.002_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.12.002_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transpl"},{"issue":"18","key":"10.1053\/j.ackd.2019.12.002_bib21","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ackd.2019.12.002_bib22","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/j.1432-2277.2011.01290.x","article-title":"Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation","volume":"24","author":"Biglarnia","year":"2011","journal-title":"Transpl Int"},{"issue":"10","key":"10.1053\/j.ackd.2019.12.002_bib23","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","article-title":"Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant","volume":"44","author":"Stewart","year":"2012","journal-title":"Transpl Proc"},{"issue":"8","key":"10.1053\/j.ackd.2019.12.002_bib24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"issue":"10","key":"10.1053\/j.ackd.2019.12.002_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation"},{"issue":"6","key":"10.1053\/j.ackd.2019.12.002_bib26","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","article-title":"Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience","volume":"47","author":"Yelken","year":"2015","journal-title":"Transpl Proc"},{"key":"10.1053\/j.ackd.2019.12.002_bib27","first-page":"9874261","article-title":"Eculizumab for the treatment of severe antibody-mediated rejection: A case report and review of the literature","volume":"2016","author":"Tran","year":"2016","journal-title":"Case Rep Transplant"},{"issue":"9","key":"10.1053\/j.ackd.2019.12.002_bib28","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.transproceed.2016.03.028","article-title":"Dosing eculizumab for antibody-mediated rejection in kidney transplantation: a case report","volume":"48","author":"Smith","year":"2016","journal-title":"Transpl Proc"},{"issue":"3","key":"10.1053\/j.ackd.2019.12.002_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.12.002_bib30","first-page":"886","article-title":"C1 inhibitor, a multi-functional serine protease inhibitor","volume":"104","author":"Davis","year":"2010","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1053\/j.ackd.2019.12.002_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.ackd.2019.12.002_bib32","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transpl"},{"issue":"12","key":"10.1053\/j.ackd.2019.12.002_bib33","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following\u00a0kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.12.002_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-6143.2009.02958.x","article-title":"Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice","volume":"10","author":"Hirohashi","year":"2010","journal-title":"Am J Transpl"},{"issue":"13","key":"10.1053\/j.ackd.2019.12.002_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.12.002_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2015.02.004","article-title":"The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection","volume":"21","author":"Thomas","year":"2015","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.12.002_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.12.002_bib39","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.pmed.1002572","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis","volume":"15","author":"Bouquegneau","year":"2018","journal-title":"Plos Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.12.002_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ajt.14979","article-title":"Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: diagnostic misinterpretation has potential therapeutic implications","volume":"19","author":"Schinstock","year":"2019","journal-title":"Am J Transpl"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519302290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519302290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:01:46Z","timestamp":1761548506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519302290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1548559519302290"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.12.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement-Based Therapy in the Management of Antibody-Mediated Rejection","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}